Clozapine: Mechanisms of Toxicity and Side Effects
https://doi.org/10.15360/1813-9779-2018-2-35-45
Abstract
Clozapine is an atypical antipsychotic agent with a confirmed effectiveness which is widely used in the clinical practice. However, its administration is associated with a high risk of serious adverse events. Life-threatening conditions related to administration of clozapine may be a result of idiosyncrasy, acute poisoning resulting from unintentional overdose of the prescribed dug, suicidal behavior, and criminal actions. The review presents current data on the mechanism of therapeutic and toxic effect of clozapine. It describes the effect of clozapine on cell receptors and ultracellular structures. It dwells on the contribution of major and intermediate metabolites of this medicinal agent to the development of toxic effects.
About the Authors
A. S. Babkina
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology;
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
25 Petrovka Str., Build. 2, 107031 Moscow;
6 Miklukho-Maсlaya Str., 117198 Moscow
A. M. Golubev
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology;
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
25 Petrovka Str., Build. 2, 107031 Moscow;
6 Miklukho-Maсlaya Str., 117198 Moscow
D. V. Sundukov
Peoples’ Friendship University of Russia
Russian Federation
6 Miklukho-Maсlaya Str., 117198 Moscow
Russian Federation
6 Miklukho-Maсlaya Str., 117198 Moscow
A. R. Bashirova
Peoples’ Friendship University of Russia
Russian Federation
6 Miklukho-Maсlaya Str., 117198 Moscow
Russian Federation
6 Miklukho-Maсlaya Str., 117198 Moscow
M. A. Golubev
Corporation «Medical electronic data»
Russian Federation
4 Sretensky tupik, Moscow 107045
Russian Federation
4 Sretensky tupik, Moscow 107045
References
1. Tochilov V.A., Kushnir O.N. Сlozapine as a first-choice medication in the treatment of patients with acute psychoses. Sotsialnaya i Klinicheskaya Psikhiatriya. 2011; 21 (2): 37-42. [In Russ.]
2. Campbell M., Young P.I., Bateman D.N., Smith J.M., Thomas S.H. The use of atypical antipsychotics in the management of schizophrenia. Br. J. Clin. Pharmacol. 1999; 47 (1): 13–22. DOI: 10.1046/j.1365-2125.1999.00849.x. PMID: 10073734
3. Green A., Tohen M., Patel J.K., Banov M., DuRand C., Berman I., Chang H., Zarate C., Posener J., Lee H., Dawson R., Richards C., Cole J.O., Schatzberg A.F. Clozapine in the treatment of refractory psychotic mania. Am. J. Psychiatry. 2000; 157 (6): 982-986. DOI: 10.1176/appi.ajp.157.6.982. PMID: 10831480
4. Szota A., Ogłodek E., Araszkiewicz A. Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine. Pharmacol. Rep. 2013; 65 (2): 279-287. DOI: 10.1016/S1734-1140(13)71004-1. PMID: 23744413
5. Abdel-Wahab B.A., Metwally M.E. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-κβ. Cardiovasc. Toxicol. 2015; 15 (4): 355-365. DOI: 10.1007/s12012-014-9304-9. PMID: 25539628
6. Abdel-Wahab B.A., Metwally M.E. Clozapine-induced cardiotoxicity in rats: involvement of tumour necrosis factor alpha, NF-κβ and caspase-3. Toxicol. Rep. 2014; 1: 1213-1223. DOI: 10.1016/j.toxrep.2014.11.012. PMID: 28962331
7. Romanova O.L., Sundukov D.V., Golubev A.M., Babkina A.S., Golubev M.A. Morphological changes in the heart with clozapine poisoning (experimental study). Obshchaya Reanimatologiya = General Reanimatology. 2017; 13 (2): 6-13. DOI: 10.15360/1813-9779-2017-2-6-13. [In Russ., In Engl.]
8. Romanova O.L., Sundukov D.V., Golubev A.M., Blagonravov M.L., Golubev M.A. Characteristics of general pathological processes in the lungs following clozapine poisoning. Obshchaya Reanimatologiya = General Reanimatology. 2017; 13 (4): 22-29. DOI: 10.15360/1813-9779-2017-4- 22-29. [In Russ., In Engl.]
9. Danilov D.S. A current view on the history of atypical antipsychotics. Zhurnal Nevrologii i Psikhiatrii Imeni S.S.Korsakova. 2017; 117 (5): 85 – 93. DOI: 10.17116/jnevro20171175185-93. PMID: 28638038. [In Russ.]
10. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist. Psychiatry. 2007; 18 (1): 39-60. DOI: 10.1177/0957154X07070335. PMID: 17580753
11. Nucifora F.C.Jr., Mihaljevic M., Lee B., Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017; 14 (3): 750-761. DOI: 10.1007/s13311-017-0552-9. PMID: 28653280
12. Hippius H. The history of clozapine. Psychopharmacology (Berl.). 1989; 99 Suppl: S3-S5. DOI: 10.1007/BF00442551. PMID: 2682730
13. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988; 45 (9): 789-796. DOI: 10.1001/archpsyc.1988.01800330013001. PMID: 3046553
14. Meltzer H.Y., Cola P., Way L., Thompson P.A., Bastani B., Davies M.A., Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatry. 1993; 150 (11): 1630-1638. DOI: 10.1176/ajp.150.11.1630. PMID: 8105705
15. Khan A.A., Ashraf A., Baker D., Al-Omary M.S., Savage L., Ekmejian A., Singh R.S.H., Brienesse S., Majeed T., Gordon T., Drinkwater V., Collins N.J. Clozapine and incidence of myocarditis and sudden death — long term Australian experience. Int. J. Cardiol. 2017; 238: 136-139. DOI: 10.1016/j.ijcard.2017.03.013. PMID: 28343762
16. Katta N., Balla S., Aggarwal K. Clozapine-induced hypersensitivity myocarditis presenting as sudden cardiac death. Autops. Case Rep. 2016; 6 (4): 9-13. DOI: 10.4322/acr.2016.054. PMID: 28210568
17. Acciavatti T., Martinotti G., Corbo M., Cinosi E., Lupi M., Ricci F., Di Scala R., D’Ugo E., De Francesco V., De Caterina R., di Giannantonio M. Psychotropic drugs and ventricular repolarisation: the effects on QT interval, T-peak to T-end interval and QT dispersion. J. Psychopharmacol. 2017; 31 (4): 453-460. DOI: 10.1177/0269881116684337. PMID: 28071178
18. Woloszyn E., Whig N., Trigoboff E., Grace J.J. Cardiac arrest with clozapine and olanzapine: revealing long QT syndrome. Clin. Schizophr. Relat. Psychoses. 2016; Dec. 20. [Epub. ahead of print]. DOI: 10.3371/CSRP. WOWH.112316. PMID: 27996317
19. Grande I., Pons A., Baeza I., Torras Á., Bernardo M. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum. Psychopharmacol. 2011; 26 (6): 397-403. DOI: 10.1002/hup.1221. PMID: 21826738
20. Lee S.Y., Kim Y.J., Kim K.T., Choe H., Jo S.H. Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br. J. Pharmacol. 2006; 148 (4): 499-509. DOI: 10.1038/sj.bjp.0706744. PMID: 16633353
21. Shulman M., Jennifer Njoku I., Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med. 2013; 104 (2): 175- 184. PMID: 23514994
22. Hu Q., Zhang C., Zhu S. Fatal multisystem venous thrombosis associated w ith clozapine. J. Clin. Psychopharmacol. 2013; 33 (2): 256-258. DOI: 10.1097/JCP.0b013e318285683b. PMID: 23422385
23. Allenet B., Schmidlin S., Genty C., Bosson J.L. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol. Drug Saf. 2012; 21 (1): 42-48. DOI: 10.1002/pds.2210. PMID: 22052683
24. Werring D., Hacking D., Losseff N., Jäger H.R., Walsh M., Foong J. Cerebral venous sinus thrombosis may be associated with clozapine. J. Neuropsychiatry Clin. Neurosci. 2009; 21 (3): 343-345. DOI: 10.1176/jnp.2009.21.3.343a. PMID: 19776318
25. Axelsson S., Hägg S., Eriksson A.C., Lindahl T.L., Whiss P.A. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin. Exp. Pharmacol. Physiol. 2007; 34 (8): 775-780. DOI: 10.1111/j.1440-1681.2007.04650.x. PMID: 17600556
26. Swart L.E., Koster K., Torn M., Budde R.P.J., Uijlings R. Clozapine-induced myocarditis. Schizophr. Res. 2016; 174 (1-3): 161-164. DOI: 10.1016/j.schres.2016.04.016. PMID: 27112636
27. Barry A.R., Windram J.D., Graham M.M. Clozapine-associated myocarditis: case report and literature review. Can. J. Hosp. Pharm. 2015; 68 (5): 427-429. DOI: 10.4212/cjhp.v68i5.1493. PMID: 26478592
28. Longhi S., Heres S. Clozapine-induced, dilated cardiomyopathy: a case report. BMC Res. Notes. 2017; 10 (1): 338. DOI: 10.1186/s13104-017- 2679-5. PMID: 28750684
29. West S., Jeffery-Smith A., Brownlee W., Kenedi C. Covert clozapine overdose: Clozapine toxicity in a naive patient. Aust. N.Z. J. Psychiatry. 2013; 47 (12): 1208-1209. DOI: 10.1177/0004867413495926. PMID: 23817859
30. McElroy S.L., Dessain E.C., Pope H.G.Jr., Cole J.O., Keck P.E.Jr., Frankenberg F.R., Aizley H.G., O’Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry. 1991; 52 (10): 411-414. PMID: 1938976
31. Seeman P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem. Neurosci. 2014; 5 (1): 24-29. DOI: 10.1021/cn400189s. PMID: 24219174
32. Dziewczapolski G., Menalled L.B., Savino M.T., Mora M., Stefano F.J., Gershanik O. Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the «super-off» phenomenon. Mov. Disord. 1997; 12 (2): 159-166. DOI: 10.1002/mds.870120205. PMID: 9087973
33. Hermann B., Wetzel C.H., Pestel E., Zieglgänsberger W., Holsboer F., Rupprecht R. Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem. Biophys. Res. Commun. 1996; 225 (3): 957-960. DOI: 10.1006/bbrc.1996.1278. PMID: 8780717
34. Schmid C.L., Streicher J.M., Meltzer H.Y., Bohn L.M. Clozapine acts as an ag- onist at serotonin 2A receptors to counter MK-801-induced behaviors through a arrestin2-independent activation of akt. Neuropsychopharmacology. 2014; 39 (8): 1902-1913. DOI: 10.1038/npp.2014.38. PMID: 24531562
35. Kozlova S.N. Comorbidity of depression, anxiety and ischemic heart disease (literature review). Part I1. Psikhicheskie Rasstroistva v Obshchei Meditsine. 2012; 3: 44-52. [In Russ.]
36. Humbert-Claude M., Davenas E., Gbahou F., Vincent L., Arrang J.M. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl.). 2012; 220 (1): 225-241. DOI: 10.1007/s00213-011-2471-5. PMID: 21912901
37. Luzhnikov E.A. Medical toxicology. National guide. Moscow: GEOTARMedia; 2012: 528 – 530. [In Russ.]
38. Bonitenko Yu.Yu., Bonitenko E.Yu., Batotsyrenov B.V. Poisoning with azaleptin. Clinic, diagnosis, treatment. Toksikologiya. 2006; 7 (2): 29–37. [In Russ.]
39. Guidotti A., Dong E., Tueting P., Grayson D.R. Modeling the molecular epigenetic profile of psychosis in prenatally stressed mice. Prog. Mol. Biol. Transl. Sci. 2014; 128: 89-101. DOI: 10.1016/B978-0-12-800977- 2.00004-8. PMID: 25410542
40. Dong E., Nelson M., Grayson D.R., Costa E., Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. USA. 2008; 105 (36): 13614-13619. DOI: 10.1073/pnas.0805493105. PMID: 18757738
41. Dragovic S., Gunness P., Ingelman-Sundberg M., Vermeulen N.P., Commandeur J.N. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab. Dispos. 2013; 41 (3): 651-658. DOI: 10.1124/dmd.112.050484. PMID: 23297297
42. Leung J.G., Nelson S., Takala C.R., Gören J.L. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann. Pharmacother. 2014; 48 (6): 801-805. DOI: 10.1177/1060028014526701. PMID: 24619948
43. Fang J. Metabolism of clozapine by rat brain: the role of flavin-containing monooxygenase (FMO) and cytochrome P450 enzymes. Eur. J. Drug Metab. Pharmacokinet. 2000; 25 (2): 109-114. DOI: 10.1007/ BF03190076. PMID: 11112091
44. Fang J., Coutts R.T., McKenna K.F., Baker G.B. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn. Schmiedebergs Arch. Pharmacol. 1998; 358 (5): 592-599. DOI: 10.1007/PL00005298. PMID: 9840430
45. Urichuk L., Prior T.I., Dursun S., Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 2008; 9 (5): 410-418. DOI: 10.2174/138920008784746373. PMID: 18537577
46. Regen F., Herzog I., Hahn E., Ruehl C., Le Bret N., Dettling M., Heuser I., Hellmann-Regen J. Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in vitro approach. Toxicol. Appl. Pharmacol. 2017; 316: 10-16. DOI: 10.1016/j.taap. 2016.12.003. PMID: 27939987
47. Williams D.P., O’Donnell C.J., Maggs J.L., Leeder J.S., Uetrecht J., Pirmohamed M., Park B.K. Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. Chem. Res. Toxicol. 2003; 16 (10): 1359-1364. DOI: 10.1021/tx034035z. PMID: 14565776
48. Shad M.U. Clozapine toxicity: a discussion of pharmacokinetic factors. Asian J. Psychiatr. 2008; 1 (2): 47-49. DOI: 10.1016/j.ajp.2008.09.001. PMID: 23050996
49. Krivoy A., Gaughran F., Weizman A., Breen G., MacCabe J. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. Int. Clin. Psychopharmacol. 2016; 31 (4): 179-184. DOI: 10.1097/YIC.0000000000000065. PMID: 25563806
50. Khaldi S., Kornreich C., Choubani Z., Gourevitch R. Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. Encephale. 2008; 34 (6): 618-624. DOI: 10.1016/j.encep.2007.11.007. PMID: 19081460
51. Farver D. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert. Opin. Drug Saf. 2003; 2 (1): 21-35. DOI: 10.1517/1 4740338.2.1.21. PMID: 12904122
52. Elmorsy E., Smith P.A. Bioenergetic disruption of human micro-vascular endothelial cells by antipsychotics. Biochem. Biophys. Res. Commun. 2015; 460 (3): 857-862. DOI: 10.1016/j.bbrc.2015.03.122. PMID: 25824037
53. Pirmohamed M., Park K. Mechanism of clozapine-induced agranulocytosis: current status of research and implications for drug development. CNS Drugs. 1997; 7 (2): 139-158. DOI: 10.2165/00023210-199707020- 00005. PMID: 23338132
54. Girardin F.R., Poncet A., Perrier A., Vernaz N., Pletscher M., Samer C., Lieberman J.A., Villard J. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics J. 2018 Jan. 3; [Epub ahead of print]. DOI: 10.1038/s41397-017-0004-2. PMID: 29298994
55. Youssef D.L., Narayanan P., Gill N. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australas. Psychiatry. 2016; 24 (2): 176-180. DOI: 10.1177/1039856215604480. PMID: 26400457
56. Hatton J.L., Bhat P.K., Gandhi S. Clozapine-induced myocarditis: recognizing a potentially fatal adverse reaction. Tex. Heart Inst. J. 2015; 42 (2): 155-157. DOI: 10.14503/THIJ-13-3633. PMID: 25873829
57. Nemani K.L., Greene M.C., Ulloa M., Vincenzi B., Copeland P.M., Al-Khadari S., Henderson D.C. Clozapine, diabetes mellitus, cardiovascular risk and mortality: results of a 21-year naturalistic study in patients with schizophrenia and schizoaffective disorder. Clin. Schizophr. Relat. Psychoses. 2017; Nov. 22. [Epub ahead of print]. DOI: 10.3371/CSRP.KNMG.111717. PMID: 29164928
58. Hyde N., Dodd S., Venugopal K., Purdie C., Berk M., O’Neil A. Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study. Curr. Drug Saf. 2015; 10 (2): 125-131. DOI: 10.2174/157488631002150515120209. PMID: 25986036
59. Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007; 30 (1): 47-57. PMID: 17194170
60. Markovic J., Momcilov-Popin T., Mitrovic D., Ivanovic-Kovacevic S., Sekuli S., Stojsic-Milosavljevic A. Clozapine-induced pericarditis. Afr. J. Psychiatry. (Johannesbg). 2011; 14 (3): 236-238. DOI: 10.4314/ajpsy.v14i3.7. PMID: 21863209
61. Wehmeier P.M., Heiser P., Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J. Clin. Pharm. Ther. 2005; 30 (1): 91-96. DOI: 10.1111/j.1365-2710.2004.00616_1.x. PMID: 15659009
62. Kelly D.L., McMahon R.P., Liu F., Love R.C., Wehring H.J., Shim J.C., Warren K.R., Conley R.R. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J. Clin. Psychiatry. 2010; 71 (3): 304-311. DOI: 10.4088/JCP. 08m04718yel. PMID: 20079332 63. Wooltorton E. Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ. 2002; 166 (9): 1185-1186. PMID: 12000254
63. Modai I., Hirschmann S., Rava A., Kurs R., Barak P., Lichtenberg P., Ritsner M. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J. Clin. Psychopharmacol. 2000; 20 (3): 325-327. DOI: 10.1097/00004714-200006000-00006. PMID: 10831019
64. Gioda C.R., de Oliveira Barreto T., Prímola-Gomes T.N., de Lima D.C., Campos P.P., CapettiniLdos S., Lauton-Santos S., Vasconcelos A.C., Coimbra C.C., Lemos V.S., Pesquero J.L., Cruz J.S. Cardiac oxidative stress is involved in heart failure induced by thiamine deprivation in rats. Am. J. Physiol. Heart Circ. Physiol. 2010; 298 (6): H2039-H2045. DOI: 10.1152/ajpheart.00820.2009. PMID: 20304817
65. Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 1996; 16 (5): 403-409. DOI: 10.1097/00004714-199610000-00011. PMID: 8889915
66. Ronaldson K.J. Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS Drugs. 2017; 31 (9): 777-795. DOI: 10.1007/s40263-017-0461-9. PMID: 28808933
67. Wang J.F., Min J.Y., Hampton T.G., Amende I., Yan X., Malek S., Abelmann W.H., Green A.I., Zeind J., Morgan J.P. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur. J. Pharmacol. 2008; 592 (1-3): 123-127. DOI: 10.1016/j.ejphar.2008.06.088. PMID: 18627770
68. Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., Pickar D., Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology. 1999; 20 (1): 29-34. DOI: 10.1016/S0893-133X(98)00047-5. PMID: 9885782
69. Simons M., Downing S.E. Coronary vasoconstriction and catecholamine cardiomyopathy. Am. Heart J. 1985; 109 (2): 297-304. DOI: 10.1016/0002-8703(85)90597-6. PMID: 3966346
70. Ishiyama S., Hiroe M., Nishikawa T., Abe S., Shimojo T., Ito H., Ozasa S., Yamakawa K., Matsuzaki M., Mohammed M.U., Nakazawa H., Kasajima T., Marumo F. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation. 1997; 95 (2): 489-496. DOI: 10.1161/01.CIR.95.2.489. PMID: 9008468
71. Patel J.J., Lisi P.A., Lathara Z., Lipchik R.J. Clozapine-induced peripheral and pleural fluid eosinophilia. Ann. Pharmacother. 2012; 46 (2): e4. DOI: 10.1345/aph.1Q642. PMID: 22274140
72. Krämer I., Rauber-Lüthy C., Kupferschmidt H., Krähenbühl S., Ceschi A. Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. Clin. Neuropharmacol. 2010; 33 (5): 230-234. DOI: 10.1097/WNF.0b013e3181f0ec55. PMID: 20689404
73. Kim D.D., White R.F., Barr A.M., Honer W.G., Procyshyn R.M. Clozapine, elevated heart rate and QTc prolongation. J. Psychiatry Neurosci. 2018; 43 (1):71-72. PMID: 29252168
74. Hägg S., Jönsson A.K., Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert. Opin. Drug Saf. 2009; 8 (5): 537- 547. DOI: 10.1517/14740330903117271. PMID: 19569978
75. Kortepeter C., Chen M., Knudsen J.F., Dubitsky G.M., Ahmad S.R., Beitz J. Clozapine and venous thromboembolism. Am. J. Psychiatry. 2002; 159 (5): 876-877. DOI: 10.1176/appi.ajp.159.5.876. PMID: 11986154
76. Belova M.V., Ilyashenko K.K., Burykina I.A., Bitkova Y.Y., Luzhnikov Y.A., Khvatov V.B. Impact of oxidative stress on hemorheological parameters in patients with acute poisonings by psychopharmacological agents. Obshchaya Reanimatologiya = General Reanimatology. 2010; 6 (4): 22 – 25. DOI: 10.15360/1813-9779-2010-4-22. [In Russ., In Engl.]
Review
For citations:
Babkina A.S., Golubev A.M., Sundukov D.V., Bashirova A.R., Golubev M.A. Clozapine: Mechanisms of Toxicity and Side Effects. General Reanimatology. 2018;14(2):35-45. (In Russ.) https://doi.org/10.15360/1813-9779-2018-2-35-45
Views:
2493
Email this article 